Lead Product(s): Defibrotide Sodium
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2020
Enrollment in the study was stopped early based on the recommendation from an IDMC, which concluded it would be highly unlikely to reach statistical significance for the primary endpoint.